KR20210068606A - 점액 점도 정상화를 위한 생성물 및 방법 - Google Patents

점액 점도 정상화를 위한 생성물 및 방법 Download PDF

Info

Publication number
KR20210068606A
KR20210068606A KR1020217016634A KR20217016634A KR20210068606A KR 20210068606 A KR20210068606 A KR 20210068606A KR 1020217016634 A KR1020217016634 A KR 1020217016634A KR 20217016634 A KR20217016634 A KR 20217016634A KR 20210068606 A KR20210068606 A KR 20210068606A
Authority
KR
South Korea
Prior art keywords
mucus
seq
thioredoxin
protein
sputum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217016634A
Other languages
English (en)
Korean (ko)
Inventor
피터 비 하이페츠
Original Assignee
오프로 테라퓨틱스 인코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오프로 테라퓨틱스 인코퍼레이션 filed Critical 오프로 테라퓨틱스 인코퍼레이션
Publication of KR20210068606A publication Critical patent/KR20210068606A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/04—Oxidoreductases acting on sulfur groups as donors (1.8) with a disulfide as acceptor (1.8.4)
    • C12Y108/0401—Adenylyl-sulfate reductase (thioredoxin) (1.8.4.10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01009—Thioredoxin-disulfide reductase (1.8.1.9), i.e. thioredoxin-reductase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Analytical Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020217016634A 2013-03-15 2014-03-17 점액 점도 정상화를 위한 생성물 및 방법 Withdrawn KR20210068606A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361792198P 2013-03-15 2013-03-15
US61/792,198 2013-03-15
PCT/US2014/030545 WO2014145735A2 (en) 2013-03-15 2014-03-17 Product and process for mucus viscosity normalization
KR1020157028723A KR20160007496A (ko) 2013-03-15 2014-03-17 점액 점도 정상화를 위한 생성물 및 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157028723A Division KR20160007496A (ko) 2013-03-15 2014-03-17 점액 점도 정상화를 위한 생성물 및 방법

Publications (1)

Publication Number Publication Date
KR20210068606A true KR20210068606A (ko) 2021-06-09

Family

ID=51527945

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217016634A Withdrawn KR20210068606A (ko) 2013-03-15 2014-03-17 점액 점도 정상화를 위한 생성물 및 방법
KR1020157028723A Ceased KR20160007496A (ko) 2013-03-15 2014-03-17 점액 점도 정상화를 위한 생성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157028723A Ceased KR20160007496A (ko) 2013-03-15 2014-03-17 점액 점도 정상화를 위한 생성물 및 방법

Country Status (11)

Country Link
US (4) US9168290B2 (https=)
EP (1) EP2968481B1 (https=)
JP (1) JP6672139B2 (https=)
KR (2) KR20210068606A (https=)
CN (1) CN105188738B (https=)
AU (1) AU2014232520B2 (https=)
CA (1) CA2906868A1 (https=)
IL (1) IL241320B (https=)
MX (1) MX377653B (https=)
RU (1) RU2750211C2 (https=)
WO (1) WO2014145735A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2968481B1 (en) * 2013-03-15 2020-11-04 Orpro Therapeutics Inc. Product and process for mucus viscosity normalization
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
US10542961B2 (en) 2015-06-15 2020-01-28 The Research Foundation For The State University Of New York System and method for infrasonic cardiac monitoring
CN106868090B (zh) * 2017-03-28 2020-09-29 王绪友 一种医学检验用痰液处理方法
CN107630065A (zh) * 2017-11-02 2018-01-26 蔡慧娜 一种在支原体液体培养时使标本均匀分散的方法
WO2019222665A1 (en) * 2018-05-17 2019-11-21 Orpro Therapeutics, Inc. Thiol-based multivalent drug delivery compositions
WO2021138682A1 (en) * 2020-01-03 2021-07-08 Orpro Therapeutics, Inc. Compositions having thioredoxin activity and related methods
CN115200954B (zh) * 2022-06-28 2025-05-06 珠海大略科技有限公司 一种降低唾液粘度的方法及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091569A (en) 1960-08-26 1963-05-28 Mead Johnson & Co Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus
US3502779A (en) 1966-08-18 1970-03-24 Calbiochem Process of mucolysis
US3683069A (en) * 1970-02-19 1972-08-08 Michel Hooreman Enzymatic products which optimize the viscosity of mucuses and their applications
US4738841A (en) * 1985-08-28 1988-04-19 Repligen Corporation Use of thioredoxin, thioredoxin-derived, or thioredoxin-like dithiol peptides in hair care preparations
US4771036A (en) 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
SE8903003D0 (sv) 1989-09-12 1989-09-12 Astra Ab Novel medical use
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5908611A (en) 1995-05-05 1999-06-01 The Scripps Research Institute Treatment of viscous mucous-associated diseases
US5985261A (en) 1996-06-28 1999-11-16 National Jewish Medical And Research Center Use of thioredoxin-like molecules for induction of MnSOD to treat oxidative damage
JPH10191977A (ja) 1997-01-14 1998-07-28 Oriental Yeast Co Ltd チオレドキシン改変体及び該改変体を含むａｐ−１の転写活性能を増強する因子
DE19711052C2 (de) 1997-03-03 1999-09-23 Hans Rommelspacher Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure als Mukolytikum
US7585645B2 (en) 1997-05-27 2009-09-08 Sembiosys Genetics Inc. Thioredoxin and thioredoxin reductase containing oil body based products
US5925334A (en) 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
CA2905585C (en) 2001-03-29 2020-02-18 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for the treatment and/or prevention of cancer or polyps
JP2005505250A (ja) 2001-05-04 2005-02-24 ゼンコー 核酸およびチオレドキシンレダクターゼ活性を有するタンパク質
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
WO2004013283A2 (en) 2002-08-02 2004-02-12 University Of Rochester Thioredoxin mutants and uses thereof
KR20050072743A (ko) 2002-09-10 2005-07-12 내셔날 쥬이쉬 메디칼 앤드 리서치 센터 점액 또는 타액의 액화를 위한 생성물 및 방법
CN1694726A (zh) * 2002-09-10 2005-11-09 国家杰威什医疗及研究中心 用于液化粘液或痰液的产品和方法
JP4273234B2 (ja) 2003-03-31 2009-06-03 独立行政法人産業技術総合研究所 チオレドキシン改変体
RU2253484C1 (ru) * 2003-09-30 2005-06-10 Российский научный центр восстановительной медицины и курортологии Министерства здравоохранения Российской Федерации Способ лечения хронического бронхолегочного процесса при врожденных пороках развития легких у детей
WO2005094269A2 (en) 2004-03-24 2005-10-13 National Jewish Medical And Research Center Mucolytic and anti-elastase compounds and methods of use thereof
WO2005121329A2 (en) 2004-06-11 2005-12-22 Syngenta Limited Method for ameliorating an inflammatory skin condition
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
GB0503640D0 (en) 2005-02-22 2005-03-30 Syngenta Ltd Improvements in or relating to organic compounds
EP2968481B1 (en) * 2013-03-15 2020-11-04 Orpro Therapeutics Inc. Product and process for mucus viscosity normalization
WO2019222665A1 (en) 2018-05-17 2019-11-21 Orpro Therapeutics, Inc. Thiol-based multivalent drug delivery compositions
WO2021138682A1 (en) 2020-01-03 2021-07-08 Orpro Therapeutics, Inc. Compositions having thioredoxin activity and related methods

Also Published As

Publication number Publication date
HK1220354A1 (zh) 2017-05-05
US12390511B2 (en) 2025-08-19
US20210254025A1 (en) 2021-08-19
WO2014145735A3 (en) 2014-12-31
US9168290B2 (en) 2015-10-27
MX2015013040A (es) 2016-05-24
NZ711983A (en) 2021-09-24
US20260027189A1 (en) 2026-01-29
IL241320B (en) 2022-02-01
WO2014145735A2 (en) 2014-09-18
AU2014232520B2 (en) 2019-04-04
US20140271599A1 (en) 2014-09-18
CA2906868A1 (en) 2014-09-18
CN105188738A (zh) 2015-12-23
RU2015143953A3 (https=) 2018-04-02
US20160230149A1 (en) 2016-08-11
CN105188738B (zh) 2025-11-07
RU2015143953A (ru) 2017-04-21
JP2016517446A (ja) 2016-06-16
JP6672139B2 (ja) 2020-03-25
AU2014232520A1 (en) 2015-09-24
IL241320A0 (en) 2015-11-30
MX377653B (es) 2025-03-11
KR20160007496A (ko) 2016-01-20
EP2968481A2 (en) 2016-01-20
EP2968481B1 (en) 2020-11-04
RU2750211C2 (ru) 2021-06-24
WO2014145735A9 (en) 2015-05-07
EP2968481A4 (en) 2016-07-13

Similar Documents

Publication Publication Date Title
US12390511B2 (en) Product and process for mucus viscosity normalization
US9289471B2 (en) Product and process for liquefaction of mucus or sputum
US11814657B2 (en) Modified DNase and uses thereof
JP2025182217A (ja) チオレドキシン活性を有する組成物および関連方法
HK1220354B (en) Product and process for mucus viscosity normalization
NZ711983B2 (en) Product and process for mucus viscosity normalization
HK40081004A (en) Compositions having thioredoxin activity and related methods

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210531

Application number text: 1020157028723

Filing date: 20151012

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid